Chronic hepatitis C (CHC) afflicts millions of people in the United States. It is a significant public health issue, because CHC can evolve into states that are associated with cirrhosis, hepatic fibrosis and hepatocellular carcinoma (HCC). The incidence of deaths from HCV infections is increasing, and, since 2007, the number of people who die from HCV infection in the United States each year has exceeded the numbers who die from HIV infection. While significant progress has been made in the treatment of CHC, many clinicians with HCV-infected patients are not aware of the full range of complex and emerging management and treatment options available or how to apply them to various patient scenarios. Furthermore, infected patients are going undiagnosed due to lack of education and resources surrounding screening and diagnostic testing for CHC. Due to the rapidly changing landscape of CHC management, these issues can significantly affect the treatment of patients with HCV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality and treatment costs.
These interactive, case-based programs will educate clinicians on the most critical aspects of HCV prevention, management and treatment. The information and opinions provided are intended to improve a clinician's ability to prevent, diagnose and manage HCV infection. Participants will gain an increased understanding of the optimal management skills needed to treat various types of patients with CHC, which is expected to result in improved patient care, reduces morbidity and mortality, reduced costs and meaningful improvement in patient outcomes.
This program will utilize a blended learning format. Participants attending these live programs will be asked to view the online CME course prior to the program date. This will maximize the learning experience and allow for greater discussion and interaction among the audience. The online program can be found at www.viraled.com/HCVScourge2016.
After completing this activity, the participant should be better able to:
| Thursday, Sept. 22, 2016 Baltimore, MD |
Thursday, Oct. 6, 2016 Los Angeles, CA |
|
| Thursday, Sept. 22, 2016 San Francisco, CA |
Wednesday, Oct. 12, 2016 Phoenix, AZ |
|
|
Wednesday, Oct. 5, 2016 Anaheim, CA |
Thursday, Oct. 13, 2016 Chicago, IL |
|
| Tuesday, Oct. 18, 2016 New York, NY |
Tuesday, Nov. 11, 2016 Miami, FL |
|
Nezam H. Afdhal, MD |
Sammy Saab, MD Professor of Medicine and Surgery The Pfleger Liver Institute David Geffen School of Medicine University of California, Los Angeles Los Angeles, California |
|
Maurizio Bonacini, MD Medical Director Charles Drew Medical Center Los Angeles, California |
Mark Sulkowski, MD Professor of Medicine and Medical Director Viral Hepatitis Center Johns Hopkins University School of Medicine Baltimore, Maryland |
|
Lennox Jeffers, MD Chief of Hepatology Miami VA Medical Center Associate Chief Center for Liver Disease Professor of Medicine University of Miami's School of Medicine Miami, Florida |
John M. Vierling, MD Professor of Medicine Professor of Surgery Chief of Hepatology Director of Advanced Liver Therapies St. Luke's Hospital Director of Baylor Liver Health Houston, Texas |
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exceptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then provide that information to the supporting pharmaceutical companies to the best of our ability.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
